fda-review-of-clinical-data-agalsidase-alfa-for-tr->fda-update-on-advertising-and-promotion-of-prescri Content Directory

FDA Update New Expectations for IRBs
FDA Review of Clinical Data Agalsidase alfa for treatment of Fabry Disease
FDA Review of Clinical Data Fragmin ® (Dalteparin sodium injection) for treatment of VTE in cancer patients
FDA Review of Clinical Data Laronidase for the treatment of Mucopolysaccharidosis I
FDA Review of Clinical Safety Data Omalizumab for treatment of Allergic Asthma Genentech, Inc.
FDA Review of NDA 21-304 Valganciclovir for the Treatment of CMV Retinitis in AIDS
FDA Review Perspective – Entecavir for Hepatitis B
FDA Review Session December 7, 2010
FDA Review Team for Genasense (G3139)
FDA Risk/Benefit Considerations
FDA Risk Communication
FDA Role in Post-licensure Vaccine Safety Evaluation
FDA’s 510(k) Process: Reform or Ruin?
FDA’s 510(k) Third-Party Review Program
FDA’s 513(g) What is it?
FDA’s Access Mechanisms When They Work – When They Don’t And Why
FDA's Add-On Inspections for 21 CFR 11
FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Overview
FDA’s Antiviral Drugs Advisory Committee Meeting
FDA’s BIMO Inspection Program and IRB Inspections
FDA’s Budget Challenge August 22, 2007 Wayne Pines
FDA’s Center for Biologics Evaluation and Research Initiatives and Current Priorities Robert A. Yetter, Ph.D. Associate
FDA’s Center for Tobacco Products
September X , 2018
FDA s Clinical Investigator Course
FDA s Clinical Investigator Course
FDA s Clinical Investigator Course
FDA s Clinical Investigator Course
FDA s Clinical Investigator Course
FDA s Clinical Investigator Course
FDA’s Clinical Investigator Course
FDA’s Criteria for Evaluation of Red Blood Cell Products
FDA’s “Critical Path” Initiative
FDA’s “Critical Path” Initiative Presentation to FDA Science Board
FDA’s Critical Path Research Initiative & Intro to the CBER Research Program
FDA’s Critical Path to Medical Product Development: Opportunities for Generic Drugs
FDA s Current Considerations of Parvovirus B19 Nucleic Acid Testing NAT
FDA’s Current Thinking on B19 NAT (Policy Pending)
FDA’s Current Thinking on B19 NAT (Policy Pending)
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee Meeting
FDA’s Final Policy on Single-Use Devices Reprocessed by Hospitals and Commercial Reprocessors
FDA’S FOOD BIOTECHNOLOGY POLICY
FDA’s Food Related Emergency Exercise – Boxed Set (FREE-B)
FDA’s Framework for Reviewing Regulations
FDA’s Framework for Reviewing Regulations
FDA’s History with Lab Developed Tests
FDA’s Medical Device Program 2013: Looking Back and Looking Ahead
FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public
FDA’s new draft guidance on best practices for selecting predicate devices for 510(k) notifications!
FDA's New Enforcement of 21 CFR Part 11
FDA's on-going Part 11 Inspection Program
FDA’s Oncologic Drugs Advisory Committee Meeting
FDA’s Osteoporosis Guidance
FDA’s Oversight of Clinical Trials Overview of GCP Bioresearch Monitoring Program
FDA’s Pesticide Program
FDA’s Pharmaceutical Inspectorate
FDA’s Policies, Procedures, and Systems: Effects on Provider and Information Technology Sectors
FDA s Proposed Revised 21 CFR 207 Rule and Electronic Drug Registration and Listing Systems e-DRLS
FDA’s Proposed Rule under FSMA for Preventive Controls Key Takeaways May 17, 2013
FDA’s Rapid Response Teams (RRT) Program Update
FDAâ€™s Refreshed Packaged Food Label
FDA’s Regulatory Development Timeline
FDA’s Revamped Medical Device Security Requirements- Gatekeeper that can Hold Medical Device’s Approval!
FDA’s Role in Encouraging Innovation in Combination Products
FDA’s Role in Plant Design Reviews
FDA’s Role in Plant Design Reviews
FDA’s Role in Plant Design Reviews
FDA’s Role in Protecting Your Child’s Health Through Safe and Effective Vaccines
FDA’s Sentinel Initiative and CBER's Analytic Epidemiology Branch
FDA’s Sentinel Initiative
FDA’s Third Annual MDUFMA Stakeholder Meeting November 17, 2005
FDA’s vCJD Risk Communication on US Plasma-Derived Factor VIII and UK Plasma-Derived Factor XI
FDA Safety and Innovation Act FDASIA
FDA Safety Event Reporting
FDA Science Board
FDA Science Board, April 2003
FDA Science Board
FDA Science Board
FDA scripts. Programming and validation of script/programs.
FDA scripts. V alidation of script/programs.
FDA Software Validation - ADB
FDA Stakeholder Meeting On Implementation of MDUFMA Review Performance Goals May 22, 2006
FDA Stakeholders Meeting on Disparities Oakland, CA February 2011
FDA Standards Development and Implementation
FDA statisticians reviewed submissions with accelerated stability testing
FDA statisticians reviewed submissions with accelerated stability testing
FDA Summary
FDA Summary
FDA Summary
FDA Sunlamp Guidance Policies: Successfully Implemented
FDA Survey of Lead in Pharmaceuticals
FDA TA Initiative Project Plan
Evolving Safety Issues Associated With Erythropoietin Products Oncology Drugs Advisory Committee May 4, 2004
FDA Team
FDA Thailand
FDA, THE PRIVATE LABORATORY AND ITS IMPACT ON TRADE
FDA Tissue Residue Reduction Efforts
FDA to CONNECT
FDA To Facilitate Timely Development Of Safe, Effective COVID-19 Vaccines
FDA to release guidance for assessing PRO’s in all clinical trials (4th quarter 2005?)
FDA Tobacco Product Regulation: Regulatory History and Overview of Pending Legislation
FDA Tox Working Group
Council of Independent Tobacco Manufacturers of America (CITMA) David M Johnson, PhD., CITMA Consultant
FDA Transmissible Spongiform Encephalopathies Advisory Committee 23rd Meeting 01 August 2011 Gaithersburg MD Donor Defe
FDA Tree Nut Risk Assessment and Human Salmonellosis
FDA TSE Advisory Committee 16 th Meeting Silver Spring MD 14 October 2004 David M. Asher, MD
FDA TSE Advisory Committee Meeting February 13, 2004; Topic 4D Minimizing the Risk of TSE in CDER - Regulated Products
FDA TSE Advisory Committee Meeting July 17, 2003 U.S. Market Dynamics for Bovine Bone Gelatin George E. Masson Preside
FDA UDI
FDA UDI
FDA Update
FDA Update
FDA Update 2011 presented by Bennett Napier, CAE
FDA Update - CDRH

Browse slideshows:
a
b
c
d
e
f
g
h
i
j
k
l
m
n
o
p
q
r
s
t
u
v
w
x
y
z
0
1
2
3
4
5
6
7
8
9